false
0001266806
0001266806
2024-03-04
2024-03-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 4, 2024 |
Vivani
Medical, Inc.
(Exact
name of Registrant as Specified in Its Charter)
Delaware |
001-36747 |
02-0692322 |
(State
or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
|
|
|
|
|
1350
S. Loop Road |
|
Alameda,
California |
|
94502 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
|
|
|
|
|
Registrant’s
Telephone Number, Including Area Code: (415) 506-8462 |
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.0001 per share |
|
VANI |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
March 4, 2024, the Board of Directors (the “Board”) of Vivani Medical, Inc. (“Vivani”) on the recommendation
of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Daniel Bradbury to fill a newly created vacancy
on the Board resulting from the expansion of the number of members of the Board from five to six. Mr. Bradbury was appointed as director
of the Company, to serve in such capacity until the annual meeting of the Company’s stockholders in 2025 or until his earlier resignation,
death or removal. Mr. Bradbury has also been appointed to serve as a member of the Audit Committee of the Board.
Mr.
Bradbury is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm and is the Executive Chairman and Co-Founder
of Equillium, Inc., a publicly traded biopharmaceutical company, focused on developing products to treat severe autoimmune
and inflammatory disorders with high unmet medical need. He has served as the Chief Executive Officer of Equillium until January 2020.
Mr. Bradbury is the former President, Chief Executive Officer, and Director of Amylin Pharmaceuticals, Inc. (“Amylin”), a
biopharmaceutical company which focused on the development of drug candidates for the treatment of serious metabolic diseases. He served
as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before
joining Amylin, he worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the
board of directors of Castle Biosciences, Inc., Equillium, Inc. and several private companies and philanthropic organizations. He earned
a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher
Education in the United Kingdom.
Mr.
Bradbury will be compensated for his service as a non-employee director in accordance with the Company’s Non-Employee Director
Compensation Policy. As a non-employee director, Mr. Bradbury is also entitled to receive annual cash retainers of $35,000 for serving
as a member of the Board and $10,000 for serving as a member of the Audit Committee of the Board.
Mr.
Bradbury has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings
between Mr. Bradbury and any other person pursuant to which he was appointed as a director of the Company.
A
copy of the Company’s press release announcing the appointment of Mr. Bradbury is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
VIVANI
MEDICAL, INC. |
|
|
|
|
Date: March 6, 2024 |
By: |
/s/
Brigid Makes |
|
|
|
Brigid
Makes
Chief
Financial Officer
(Principal
Financial and Accounting Officer) |
Exhibit
99.1
FOR
IMMEDIATE RELEASE
Vivani
Medical Appoints Daniel Bradbury to its Board of Directors
Appointment
comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management
Under
Bradbury’s leadership as CEO, Amylin Pharmaceuticals, with partner Alkermes, secured in 2012 approval of Bydureon® (exenatide
injection), the world’s first once-weekly GLP-1 receptor agonist, a class of drugs that now includes blockbusters Ozempic®,
Trulicity®, and Wegovy®
ALAMEDA,
Calif., March 6, 2024 -- (BUSINESS WIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”),
an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment
of long-time industry veteran Daniel Bradbury to its Board of Directors.
“Dan
has served as an advisor to Vivani and our legacy company, Nano Precision Medical, since 2017, and his guidance has been invaluable,”
said Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer. “As a member of Vivani’s distinguished board of
directors, Dan’s leadership expertise and deep insight and experience developing and commercializing the world’s first GLP-1
drug (exenatide injection) will continue to prove pivotal as we focus our efforts on delivering miniature, long-term GLP-1 implants for
the treatment of obesity, type 2 diabetes, and potentially, other serious chronic diseases.”
Bradbury
is the former President, Chief Executive Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on the
development of drug candidates for the treatment of serious metabolic diseases. He
served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7.1B in August
2012. Before joining Amylin in 1994, he worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals.
Bradbury
serves on the board of directors of Castle Biosciences, Inc. and Equillium, Inc., and several private companies and philanthropic organizations.
Bradbury previously served on the board of directors of Biocon Limited, Corcept Therapeutics Inc., Geron Inc., Illumina Inc. and Intercept
Pharmaceuticals Inc. He earned a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from the
University of West London in the United Kingdom.
In
addition to his new role as Board Director, Bradbury will serve on the Audit Committee of the Vivani Medical Board.
About
Vivani Medical, Inc.
Leveraging
its proprietary NanoPortal™ platform, Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules
steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve medication tolerability.
Vivani’s lead programs NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of
chronic weight management in obese or overweight patients and type 2 diabetes, respectively. Both NPM-115 and NPM-119 are exenatide
based products with a higher-dose associated with NPM-115 for the treatment of chronic weight management in obese or overweight
patients. These NanoPortalTM implants are designed to provide patients with the opportunity to realize the full potential
benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of
patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500
billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and
daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease medications face
significant challenges in achieving positive real-world effectiveness.
Vivani’s
wholly owned subsidiary Cortigent is developing targeted neurostimulation systems intended to help patients recover critical body functions.
Investigational devices include Orion®, designed to provide artificial vision to people who are profoundly blind, and a new system
intended to accelerate the recovery of arm and hand function in patients who are partially paralyzed due to stroke. Vivani continues
to assess strategic options for advancing Cortigent’s pioneering technology.
Forward-Looking
Statements
This
press release contains certain “forward-looking statements” within the meaning of the “safe harbor”
provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such
as: “target,” “believe,” “expect,” “will,” “may,”
“anticipate,” “estimate,” “would,” “positioned,” “future,” and other
similar expressions that in this press release, including statements regarding our business, products in development, including the
therapeutic potential thereof, plans to address any requests from the FDA related to the agency’s current clinical hold on
NPM-119, the initiation of the LIBERATE-1 trial and reporting of trial results, the planned development therefor, our emerging
development plans for NPM-115, NPM-139, or our plans with respect to Cortigent and its proposed initial public offering, technology,
strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations, and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others,
risks related to the development and commercialization of our products, including NPM-115 and NPM-119; delays and changes in the
development of our products, including our ability to address any requests from the FDA related to LIBERATE-1 and to commence
clinical development of NPM-119, including as a result of applicable laws, regulations and guidelines, potential delays in
submitting and receiving regulatory clearance or approval to conduct our development activities, risks related to the initiation,
enrollment and conduct of our planned clinical trials and the results therefrom; our history of losses and our ability to access
additional capital or otherwise fund our business; market conditions and the ability of Cortigent to complete its initial public
offering. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description
of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the SEC filed on
March 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by us in this press
release is based only on information currently available to the Company and speaks only as of the date on which it is made. The
Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from
time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company
Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor
Relations Contact:
Brigid A. Makes
Chief Financial Officer
investors@vivani.com
(415) 506-8462
Media
Contact:
Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com
(646)
866-4012
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Vivani Medical (PK) (USOTC:VANIW)
Historical Stock Chart
From Apr 2024 to May 2024
Vivani Medical (PK) (USOTC:VANIW)
Historical Stock Chart
From May 2023 to May 2024